Decades after receiving a childhood blood transfusion, Chris Sosinski was shocked to learn he had the hepatitis C virus, which had led to cirrhosis and the prospect of a liver transplant.
Today, Chris remains hepatitis C negative, thanks to a new direct-acting antiviral therapy he received at the UPMC Center for Liver Diseases last year.
Two drugs approved by the Food and Drug Administration (FDA) in 2011 ushered in a new era of treatment, delivering:
- Improved cure rates
- Shorter treatment time
- Better management for the hardest-to-treat strain of the virus
Playing a critical role was the UPMC Center for Liver Diseases, where specialists have been at the forefront in the evaluation and clinical trials of promising new therapies. “Over the next few years, we expect to have several new options that will eradicate the hepatitis C virus in most patients without side effects,” says Dr. Kapil Chopra, director of the Center for Liver Diseases.
In the tri-state area, UPMC is the leading provider of comprehensive and advanced specialty care for patients with the virus. “Our multidisciplinary specialists are involved in researching and evaluating new treatments. It’s a new era of treatment and hope for our patients,” explains Dr. Chopra.
For more information about these new therapies, visit the UPMC Center for Liver Diseases website or call 412-647-1170.